Gilead Sciences (FRA:GIS) Cyclically Adjusted PS Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:GIS Gilead Sciences Inc FRA:GIS
68 GF Score
Price €115.46
GF Value €82.98
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Gilead Sciences Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Gilead Sciences  (FRA:GIS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Gilead Sciences Cyclically Adjusted PS Ratio Related Terms


Gilead Sciences Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Gilead Sciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences Cyclically Adjusted PS Ratio Chart

Gilead Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.86 4.01 3.46 3.79 5.03

Gilead Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.51 4.50 5.03 5.65 5.10

FRA:GIS vs PFE, BMY, AMGN: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted PS Ratio falls into.


FRA:GIS
68GF Score
Gilead Sciences Inc FRA:GIS
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gilead Sciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Gilead Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Gilead Sciences's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.449/333.9520*333.9520
=5.449

Current CPI (Jun. 2026) = 333.9520.

Gilead Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 4.991 241.428 6.904
201612 5.237 241.432 7.244
201703 4.608 243.801 6.312
201706 4.826 244.955 6.579
201709 4.142 246.819 5.604
201712 3.811 246.524 5.163
201803 3.126 249.554 4.183
201806 3.696 251.989 4.898
201809 3.669 252.439 4.854
201812 3.940 251.233 5.237
201903 3.643 254.202 4.786
201906 3.940 256.143 5.137
201909 4.016 256.759 5.223
201912 4.153 256.974 5.397
202003 3.953 258.115 5.114
202006 3.639 257.797 4.714
202009 4.428 260.280 5.681
202012 4.762 260.474 6.105
202103 4.275 264.877 5.390
202106 4.095 271.696 5.033
202109 4.998 274.310 6.085
202112 5.080 278.802 6.085
202203 4.741 287.504 5.507
202206 4.700 296.311 5.297
202209 5.640 296.808 6.346
202212 5.514 296.797 6.204
202303 4.705 301.836 5.206
202306 4.842 305.109 5.300
202309 5.255 307.789 5.702
202312 5.198 306.746 5.659
202403 4.933 312.332 5.274
202406 5.163 314.175 5.488
202409 5.421 315.301 5.742
202412 5.652 315.605 5.981
202503 4.898 319.799 5.115
202506 4.892 322.561 5.065
202509 5.278 324.800 5.427
202512 5.405 324.054 5.570
202603 4.801 330.213 4.855
202606 5.449 333.952 5.449

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Gilead Sciences (FRA:GIS) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of €115.46 is trading 39.1% above its estimated GF Value™ of €82.98. GuruFocus considers Gilead Sciences to be Significantly Overvalued.

Key valuation signals for FRA:GIS:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €82.98 vs. price of €115.46 (39.1% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
68GF Score

Get the complete analysis for FRA:GIS

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€115.46
Price
€82.98
GF Value